A Phase 2 open-label multicenter study to evaluate efficacy and safety of zanidatamab for the treatment of participants with previously treated HER2-expressing solid tumors (DiscovHER PAN-206) (JZP598-206)
Indication: Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Breast Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Esophageal Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer, Lung Cancer
Trial Number: 06695845
Trial Status: OPEN